Antitumor Monoclonal Antibodies Enhance Cross-presentation OfcCellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2002 Jan 10

PMID 11781371

Citations 130

Authors

Kavita M Dhodapkar

Joseph Krasovsky

Barbara Williamson

Madhav V Dhodapkar

Affiliations

Soon will be listed here.

Abstract

The mechanism of antitumor effect of monoclonal antibodies (mAbs) is not fully understood. Here we show that coating myeloma cells with anti-syndecan-1 antibody promotes cross-presentation of cellular antigens by dendritic cells (DCs) to autologous T cells from healthy donors. The tumor cells treated with anti-syndecan-1 or isotype-matched control antibody were fed to HLA-mismatched monocyte-derived immature DCs. Tumor cell-loaded mature DCs induced a strong CD8(+) T cell response that was specific for the cancer-testis (C-T) antigens expressed in the tumor. The CD8(+) T cells killed peptide-pulsed targets, as well as myeloma tumor cells. Importantly, mAbs-coated tumor-loaded DCs were consistently superior to DCs loaded with peptides or dying cells for eliciting tumor-specific killer T cells. This enhanced cross-presentation was not due to enhanced tumor cell uptake or to DC maturation. When mixtures of NY-Eso-1-positive and -negative myeloma cells were captured by DCs, the anti-syndecan-1 antibody had to be on the NY-Eso-1-positive cells to elicit NY-Eso-1-specific response. Cross-presentation was inhibited by pretreatment of DCs with Fc gamma receptor blocking antibodies. Targeting of mAb-coated tumors to DCs may contribute to the efficacy of tumor-reactive mAb and offers a new strategy for immunotherapy.

Citing Articles

With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process.

Crescioli S, Jatiani S, Moise L MAbs. 2025; 17(1):2453515.

PMID: 39819511 PMC: 11810086. DOI: 10.1080/19420862.2025.2453515.

Core-Shell Chitosan Particles Targeting Membrane-Bound Heat Shock Protein 70 for Cancer Therapy.

Svirshchevskaya E, Kostenko V, Boyko A, Shevtsov M, Kholodenko R, Grechikhina M Nanomaterials (Basel). 2024; 14(23).

PMID: 39683266 PMC: 11643800. DOI: 10.3390/nano14231873.

Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies.

Hematianlarki M, Nimmerjahn F Immunol Rev. 2024; 328(1):372-386.

PMID: 39340138 PMC: 11659946. DOI: 10.1111/imr.13404.

Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.

Ghisoni E, Morotti M, Sarivalasis A, Grimm A, Kandalaft L, Dangaj Laniti D Nat Rev Clin Oncol. 2024; 21(11):801-817.

PMID: 39232212 DOI: 10.1038/s41571-024-00937-4.

Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.

Kocoglu M, Luetkens T, Bork J, Baddley J, Omili D, Gebru E Blood Adv. 2024; 8(22):5880-5884.

PMID: 39058975 PMC: 11612371. DOI: 10.1182/bloodadvances.2024012762.

References

Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S . Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1999; 1(6):362-8. DOI: 10.1038/14058. View

Albert M, Pearce S, Francisco L, Sauter B, Roy P, Silverstein R . Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998; 188(7):1359-68. PMC: 2212488. DOI: 10.1084/jem.188.7.1359. View

Amigorena S, Bonnerot C . Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol. 2000; 11(6):385-90. DOI: 10.1006/smim.1999.0196. View

Scanlan M, Altorki N, Gure A, Williamson B, Jungbluth A, Chen Y . Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 2000; 150(2):155-64. DOI: 10.1016/s0304-3835(99)00385-7. View

Machy P, Serre K, Leserman L . Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol. 2000; 30(3):848-57. DOI: 10.1002/1521-4141(200003)30:3<848::AID-IMMU848>3.0.CO;2-Q. View

Houghton A, Scheinberg D . Monoclonal antibody therapies-a 'constant' threat to cancer. Nat Med. 2000; 6(4):373-4. DOI: 10.1038/74621. View

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

Schubert U, Anton L, Gibbs J, Norbury C, Yewdell J, Bennink J . Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000; 404(6779):770-4. DOI: 10.1038/35008096. View

Hamano Y, Arase H, Saisho H, Saito T . Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J Immunol. 2000; 164(12):6113-9. DOI: 10.4049/jimmunol.164.12.6113. View

10.

Hoffmann T, Meidenbauer N, Dworacki G, Kanaya H, Whiteside T . Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000; 60(13):3542-9. View

11.

Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus W . Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood. 2000; 96(5):1857-64. View

12.

Jenne L, Arrighi J, Jonuleit H, Saurat J, Hauser C . Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 2000; 60(16):4446-52. View

13.

Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus E, Davoust J . Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000; 165(7):3797-803. DOI: 10.4049/jimmunol.165.7.3797. View

14.

Feuerstein B, Berger T, Maczek C, Roder C, Schreiner D, Hirsch U . A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods. 2000; 245(1-2):15-29. DOI: 10.1016/s0022-1759(00)00269-6. View

15.

Berard F, Blanco P, Davoust J, Neidhart-Berard E, Nouri-Shirazi M, Taquet N . Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000; 192(11):1535-44. PMC: 2193101. DOI: 10.1084/jem.192.11.1535. View

16.

Subklewe M, Paludan C, Tsang M, Mahnke K, Steinman R, Munz C . Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J Exp Med. 2001; 193(3):405-11. PMC: 2195925. DOI: 10.1084/jem.193.3.405. View

17.

Houghton A, Gold J, Blachere N . Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol. 2001; 13(2):134-40. DOI: 10.1016/s0952-7915(00)00195-3. View

18.

Wallace P, Tsang K, Goldstein J, Correale P, Jarry T, Schlom J . Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I. J Immunol Methods. 2001; 248(1-2):183-94. DOI: 10.1016/s0022-1759(00)00351-3. View

19.

Heath W, Carbone F . Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001; 19:47-64. DOI: 10.1146/annurev.immunol.19.1.47. View

20.

Ukkonen P, Lewis V, Marsh M, Helenius A, Mellman I . Transport of macrophage Fc receptors and Fc receptor-bound ligands to lysosomes. J Exp Med. 1986; 163(4):952-71. PMC: 2188083. DOI: 10.1084/jem.163.4.952. View